QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02509 QYUNS-B

Not Yet Opened 11-11 15:43:22

14.610

-0.050

-0.34%

High14.790	Low14.500	Vol22.40K
Open14.500	D1 Closing14.660	Amplitude1.98%
Mkt Cap3.26B	Tradable Cap3.26B	Total Shares223.00M
T/O328.32K	T/O Rate0.01%	Tradable Shares223.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":14.61,"timestamp":1794383002142,"preClose":14.66,"halted":0,"volume":22400,"delay":0,"changeRate":-0.003410641200545751,"floatShares":223000000,"shares":223000000,"eps":1.41,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"11-11 15:43:22","open":14.5,"high":14.79,"low":14.5,"amount":328324,"amplitude":0.019782,"askPrice":14.8,"askSize":57600,"bidPrice":14.6,"bidSize":400,"shortable":3,"etf":0,"ttmEps":2.802943,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794447000000},"marketStatusCode":0,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":14.66,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.30128584454015467,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509/tweets","defaultTab":"tweets","newsList":[{"id":"2681888201","title":"Alector Q3 Swings to Net Profit on Lower Operating Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888201","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681888201?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:58","pubTimestamp":1793915892,"startTime":"0","endTime":"0","summary":"Alector Q3 net loss narrows on lower operating expensesOverviewU.S. biotech firm's Q3 revenue surgedCompany swung to net profit from loss a year earlierAlector signed $100 mln upfront licensing deal...","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","ALEC","XNCR","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681076705","title":"China's Qyuns Therapeutics Licenses Antibody Program to Caldera in up to $780 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2681076705","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681076705?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:55","pubTimestamp":1793886959,"startTime":"0","endTime":"0","summary":"China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million dealNov 5-Qyuns Therapeutics2509.HKis licensing an early-stage antibody program to US biotech Caldera Therapeutics","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL3N46M13M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681027337","title":"Qyuns Therapeutics Co Enters Exclusive License Agreement with Caldera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027337","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681027337?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:17","pubTimestamp":1793881065,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Co Enters Exclusive License Agreement With Caldera TherapeuticsNov 5 -Qyuns Therapeutics Co Ltd2509.HK:ENTERS EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICSTO RECEIVE UPFRONT PAYMENT OF US$30 MILLIONMAY RECEIVE UP TO US$750 MILLION IN MILESTONE PAYMENTSCALDERA THERAPEUTICS GRANTED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCT CANDIDATES WORLDWIDEFurther company coverage:2509.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M2S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681302222","title":"Qyuns Therapeutics Co - May Receive up to Us$750 Mln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2681302222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681302222?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:11","pubTimestamp":1793880668,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M2S9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681022279","title":"Qyuns Therapeutics Co - Caldera Therapeutics Granted Exclusive Rights to Develop and Commercialize Product Candidates Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2681022279","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681022279?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:11","pubTimestamp":1793880668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M2S9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678174385","title":"Qyuns Therapeutics Raises Profit-Sharing Caps for Psoriasis Drug Through 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2678174385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678174385?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:42","pubTimestamp":1793101323,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  proposed raising annual profit-sharing caps for its psoriasis drug QX001S to 120 million yuan in 2026, 210 million yuan in 2027 and 310 million yuan in 2028.QX001S is a biosimilar of ustekinumab, marketed as SAILEXIN and SAIJIENING in China. The company said the revised caps reflect rising demand for the drug, according to a Wednesday Hong Kong bourse filing.Qyuns also proposed raising annual caps for drug supplies to its commercialization partner, Hangzhou Zhongmei Huadong Pharmaceutical, to 25 million yuan in 2026, 42 million yuan in 2027 and 57 million yuan in 2028. Both proposals require independent shareholder approval at a Nov. 13 meeting.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4139","02509","BK4007","BK4539","FCA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115333774","title":"Qyuns Therapeutics to Hold First 2026 EGM for Revised Connected-Transaction Caps and New Board Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=1115333774","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115333774?lang=en_us&edition=fundamental","pubTime":"2026-10-27 17:41","pubTimestamp":1793094075,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. has issued a formal notice convening its first Extraordinary General Meeting (EGM) of 2026 on Friday, 13 November 2026 at 2:00 p.m. in Room 1809, Tower A, The Place, No....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678241001","title":"Qyuns Therapeutics Proposes Ji Juan as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2678241001","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678241001?lang=en_us&edition=fundamental","pubTime":"2026-10-27 17:03","pubTimestamp":1793091835,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Proposes Ji Juan as Non-Executive DirectorQyuns Therapeutics shareholders will vote November 13, 2026, on revised QX001S transaction caps and Ji Juan's appointment as a non-executiv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDLbwYnnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168036","title":"Qyuns Therapeutics Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678168036?lang=en_us&edition=fundamental","pubTime":"2026-10-26 16:35","pubTimestamp":1793003705,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Announces Extraordinary General MeetingQyuns Therapeutics plans to hold an extraordinary general meeting on November 13, 2026.Disclaimer:This news brief was created by Public Techno","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL8g103Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167193163","title":"QYUNS-B Reports No Changes in Share Capital, Confirms Ample Public Float for September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1167193163","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167193163?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:05","pubTimestamp":1791363937,"startTime":"0","endTime":"0","summary":"Hong Kong-listed biopharmaceutical company Qyuns Therapeutics Co., Ltd. (QYUNS-B) has filed its Monthly Return for Equity Issuers for the period ended 30 September 2026, showing a stable capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672679263","title":"Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672679263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672679263?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:18","pubTimestamp":1790921909,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  reported sustained symptom improvements in a Phase III study of its Oturkibart treatment for adults with moderate-to-severe prurigo nodularis, according to a Friday exchange filing.At Week 24, 74.5% of Oturkibart patients saw reduced itching and 34.7% achieved clear or almost clear skin, compared with 29.0% and 11.1% for the placebo group, respectively. By Week 52, those efficacy rates climbed to 95.5% and 66.9% among patients continuing the treatment.The drug's safety profile was similar to the placebo, with no new long-term risks identified.Shares of the biopharmaceutical firm fell nearly 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK1161","BK4139","BK4539","BK4007","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118587788","title":"Qyuns Therapeutics Posts Strong Phase III Data for Oturkibart in Prurigo Nodularis; Results Spotlighted at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1118587788","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118587788?lang=en_us&edition=fundamental","pubTime":"2026-10-02 08:26","pubTimestamp":1790900806,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics (QYUNS-B) reported that its China Phase III trial of Oturkibart (QX005N), a humanised anti-IL-4Rα monoclonal antibody, met primary and key secondary endpoints in adults with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117582462","title":"QYUNS-B Releases Updated Director Line-Up and Board Committee Assignments","url":"https://stock-news.laohu8.com/highlight/detail?id=1117582462","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117582462?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:21","pubTimestamp":1790086914,"startTime":"0","endTime":"0","summary":"QYUNS-B (official name: Qyuns Therapeutics Co., Ltd.) has published an updated roster of its Board of Directors and detailed the latest composition of its four specialised committees. The disclosure,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127422140","title":"Hong Kong Stock Movers | QYUNS-B (02509) Jumps Over 9% in Morning Trade, BD Achievements Concentrated, First Product Sees Commercial Ramp-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1127422140","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127422140?lang=en_us&edition=fundamental","pubTime":"2026-09-14 11:06","pubTimestamp":1789355176,"startTime":"0","endTime":"0","summary":"Shares of QYUNS-B (02509) surged more than 9% during Tuesday morning trading on the Hong Kong Stock Exchange. As of press time, the stock was up 5.60% at HK$17.15, with turnover reaching HK$26.71...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","KCAI","BK4588","VXUS","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152623439","title":"QYUNS-B Reports Zero Share Movements, Affirms 25%+ Public Float in August 2026 HKEX Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1152623439","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152623439?lang=en_us&edition=fundamental","pubTime":"2026-09-04 10:42","pubTimestamp":1788489764,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) has filed its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 31 August 2026, confirming a stable capital structure and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198410369","title":"Autoimmune Drug Leader Delivers on Long-Term Vision: QYUNS-B's Revenue Doubling and the Dual-Engine Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1198410369","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198410369?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:00","pubTimestamp":1787295634,"startTime":"0","endTime":"0","summary":"The global autoimmune drug market continues to expand at a scale of hundreds of billions of US dollars, yet the penetration rate of biologics in the Chinese market remains below 30%, creating a stark...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661318892","title":"Qyuns Therapeutics (SEHK:2509) Stock Turns Profitable While Forecasts Cloud The Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661318892","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661318892?lang=en_us&edition=fundamental","pubTime":"2026-08-21 01:26","pubTimestamp":1787246768,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics came into this earnings print with a profitable twelve month track record and a stock that has drifted, with the share price down about 6.6% over the past week but still modestly higher over three months. The headline this half is simple: the company delivered H1 2026 revenue of C¥424.1m and net income of C¥203.3m, which keeps the recent profitability story intact.\nThe tension for you as an investor sits between those solid trailing numbers and a stock valued at roughly...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-stock-turns-profitable-while-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-stock-turns-profitable-while-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","LENZ","02509","BK4539","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131832342","title":"QYUNS-B (02509) Posts Interim Net Profit of RMB 203 Million, Reversing Year-Ago Loss as Its \"QYUNS 1.0\" Strategy Takes Shape","url":"https://stock-news.laohu8.com/highlight/detail?id=1131832342","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131832342?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:37","pubTimestamp":1787146658,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) has reported its financial results for the six months ended June 30, 2026, showing revenue of RMB 424 million, a 105.37% increase year-over-year. The company recorded a profit...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119580438","title":"QYUNS Interim: Licensing Windfall Drives Turn-Round to RMB198.57 Million Profit, Revenue Doubles","url":"https://stock-news.laohu8.com/highlight/detail?id=1119580438","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119580438?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:27","pubTimestamp":1787146072,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (abbrev. “QYUNS”) reported unaudited interim results for the six months ended 30 June 2026. Financial Highlights   • Revenue surged 105.4% year-on-year to RMB424.06...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"QYUNS Interim: Licensing Windfall Drives Turn-Round to RMB198.57 Million Profit, Revenue Doubles","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542519","title":"QYUNS Therapeutics Posts HY Adjusted Profit of Rmb202.5 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542519?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:18","pubTimestamp":1787145504,"startTime":"0","endTime":"0","summary":"BRIEF-QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLNAug 19 (Reuters) - QYUNS Therapeutics HY Adjusted profit RMB202.5 MLN.QYUNS Therapeutics HY Revenue 424.1 MLN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXSCVV4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.1283},{"period":"3month","weight":-0.187},{"period":"6month","weight":-0.1486},{"period":"1year","weight":-0.2335},{"period":"ytd","weight":-0.222}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Qyuns Therapeutics Co Ltd is a China-based company principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases. The Company focuses on dermatology, respiratory, gastroenterology and rheumatology diseases. The Company's products include SAILEXIN, Oturkibart, and Crusekitug. The Company conducts its businesses in domestic and overseas markets.","exchange":"SEHK","name":"QYUNS-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"QYUNS-B,02509,QYUNS-B股票,QYUNS-B股票老虎,QYUNS-B股票老虎国际,QYUNS-B行情,QYUNS-B股票行情,QYUNS-B股价,QYUNS-B股市,QYUNS-B股票价格,QYUNS-B股票交易,QYUNS-B股票购买,QYUNS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}